Daré Bioscience(DARE) - 2025 Q1 - Quarterly Results

● Four on-market products will accelerate revenue generation and provide path to profitability Exhibit 99.1 Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 ● Creates commercial opportunity in the estimated up to $4.5 billion compounded hormo ...